<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Feldman, Ted</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">EVEREST Trial 2-Year Results Show Stability of Percutaneous MV Repair between Years 1 and 2</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">The 2-year results from the Endovascular Valve Edge-to-Edge Repair trial [EVEREST II; NCT00209274] showed that percutaneous mitral valve repair is safe and durable with measurable clinical benefits and is a therapeutic option for select patients with significant mitral regurgitation [Feldman T et al. N Engl J Med 2011].</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>